University College London Hospital
London, United Kingdom
45 recruiting
Showing 1–20 of 73 trials
Recruiting
Phase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
ObesityHeart Failure With Preserved Ejection FractionHeart Failure With Mildly Reduced Ejection Fraction
Amgen5,056 enrolled628 locationsNCT07037459
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Relapsed or Refractory Multiple Myeloma (RRMM)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company440 enrolled141 locationsNCT06615479
Recruiting
Phase 1Phase 2
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Colorectal, CancerColorectal CarcinomaNon-small Cell Lung Cancer+29 more
Institut de Recherches Internationales Servier554 enrolled27 locationsNCT05786924
Recruiting
Phase 4
Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
Desmoid TumorAggressive Fibromatosis
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany50 enrolled23 locationsNCT07176689
Recruiting
Not Applicable
PMCF Study of the Axonics SNM System Model 5101 (R20) for the Indication of OAB
Overactive Bladder (OAB)Urinary Urge Incontinence (UUI)Urinary Frequency (UF)
Axonics, Inc.55 enrolled5 locationsNCT06789406
Recruiting
Phase 3
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb850 enrolled256 locationsNCT07361497
Recruiting
Phase 1
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Ewing SarcomaColorectal Adenocarcinoma
Inhibrx Biosciences, Inc411 enrolled36 locationsNCT03715933
Recruiting
Phase 3
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Lymphoma
Hoffmann-La Roche182 enrolled77 locationsNCT06084936
Recruiting
Phase 3
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Myelodysplastic Syndromes (MDS)Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)
Institut de Recherches Internationales Servier48 enrolled62 locationsNCT06465953
Recruiting
Phase 1
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Endometrial CancerTesticular CancerPlatinum Resistant Ovarian Cancer
Context Therapeutics Inc.156 enrolled14 locationsNCT06515613
Recruiting
Phase 1Phase 2
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Multiple Myeloma
Celgene62 enrolled22 locationsNCT06988488
Recruiting
Phase 3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Carcinoma, Non-Small Cell Lung
Mirati Therapeutics Inc.630 enrolled351 locationsNCT06875310
Recruiting
Phase 1Phase 2
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Advanced Lung Cancer
BioNTech SE594 enrolled88 locationsNCT06892548
Recruiting
Phase 3
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Urinary Bladder NeoplasmsNeoplasm MetastasisCarcinoma, Transitional Cell
Eli Lilly and Company450 enrolled286 locationsNCT07218380
Recruiting
Phase 2Phase 3
A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
Sickle Cell Disease
Pfizer389 enrolled49 locationsNCT05431088
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
CancerCarcinoma, Non-Small Cell LungOvarian Neoplasms+17 more
Cancer Research UK30 enrolledNCT07440290
Recruiting
Determining the Mechanisms of Loss of CAR T Cell Persistence
Acute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia, PediatricAcute Lymphoblastic Leukemia, Adult+2 more
University College, London50 enrolled3 locationsNCT05809284
Recruiting
Phase 1
Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies
Blood Cancer
University College, London12 enrolledNCT05391490
Recruiting
Phase 1
Multi-modular Chimeric Antigen Receptor T Cells tarGeting B7-H3 in Children, Teenage & Young Adult Sarcoma
Sarcoma
University College, London12 enrolledNCT07751380
Recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Myasthenia GravisMultiple Sclerosis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company120 enrolled35 locationsNCT06220201